secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2023-06-14T23:59:59+00:00
Accession:  0000950170-23-027958
Event type: leadership
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.02, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology transitions CSO Patrick Baeuerle to advisor; stockholders elect directors
--------------------------------------------------------------------------------

- Dr. Baeuerle transitions from Chief Scientific Officer to Co-Founder & Chief Scientific Advisor, effective June 8, 2023.
- Consulting agreement: $40,556 monthly, max $480,000/year, with bonus opportunity (40% in 2023, 25% thereafter).
- Stockholders elected Nadim Ahmed (28,651,746 votes for) and Stephen Webster (21,598,415 for) as Class III directors.
- Ratification of KPMG LLP as independent auditor for FY2023 approved with 34,563,271 votes for.
- Term of consulting agreement runs through Dec 31, 2024, with annual auto-renewal; either party may terminate on 180 days notice.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017023027958/0000950170-23-027958-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017023027958/cgem-20230608.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027958

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer